Cytokine Modulation of Atopic Dermatitis Filaggrin Skin Expression

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2007 May 22

PMID 17512043

Citations 225

Authors

Michael D Howell

Byung Eui Kim

Peisong Gao

Audrey V Grant

Mark Boguniewicz

Anna DeBenedetto

Lynda Schneider

Lisa A Beck

Kathleen C Barnes

Donald Y M Leung

Affiliations

Soon will be listed here.

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by a defective skin barrier function. Recent studies have reported mutations of the skin barrier gene encoding filaggrin in a subset of patients with AD.

Objective: We investigated whether reduced filaggrin expression was found in patients with AD who were not carriers of known filaggrin mutations and whether filaggrin expression was modulated by the atopic inflammatory response.

Methods: Filaggrin expression was measured in skin biopsies and cultured keratinocytes using real-time RT-PCR and immunohistochemistry. Filaggrin loss-of-function mutations were screened in a total of 69 subjects.

Results: Compared with normal skin, filaggrin expression was significantly reduced (P < .05) in acute AD skin, with further reduction seen in acute lesions from 3 European American subjects with AD who were heterozygous for the 2282del4 mutation. This was confirmed by using immunohistochemistry. AD skin is characterized by the overexpression of IL-4 and IL-13. Keratinocytes differentiated in the presence of IL-4 and IL-13 exhibited significantly reduced filaggrin gene expression (0.04 +/- 0.01 ng filaggrin/ng glyceraldehyde 3-phosphate dehydrogenase; P < .05) compared with media alone (0.16 +/- 0.03).

Conclusion: Patients with AD have an acquired defect in filaggrin expression that can be modulated by the atopic inflammatory response.

Clinical Implications: The atopic immune response contributes to the skin barrier defect in AD; therefore, neutralization of IL-4 and IL-13 could improve skin barrier integrity.

Citing Articles

Effects of Earthworm () extract on atopic dermatitis: An in vitro and in vivo study.

Sung Y, Yuk H, Kim S, Kim D Heliyon. 2025; 11(1):e41140.

PMID: 39758409 PMC: 11699427. DOI: 10.1016/j.heliyon.2024.e41140.

Efficacy and Safety of Topical Application of Plant-Based Products on Skin Aging in Healthy Individuals: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Cheng F, Feng J, Cao Z, Duan Q, Li H J Cosmet Dermatol. 2024; 24(2):e16710.

PMID: 39654386 PMC: 11845950. DOI: 10.1111/jocd.16710.

Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.

Speeckaert R, Belpaire A, Lambert J, Speeckaert M, van Geel N Immune Netw. 2024; 24(5):e33.

PMID: 39513029 PMC: 11538609. DOI: 10.4110/in.2024.24.e33.

Skin Lipid Barrier: Structure, Function and Metabolism.

Berdyshev E Allergy Asthma Immunol Res. 2024; 16(5):445-461.

PMID: 39363765 PMC: 11450438. DOI: 10.4168/aair.2024.16.5.445.

Therapeutic Potential and Mechanisms of Mesenchymal Stem Cell and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Atopic Dermatitis.

He K, Zang J, Ren T, Feng S, Liu M, Zhang X J Inflamm Res. 2024; 17:5783-5800.

PMID: 39224661 PMC: 11368146. DOI: 10.2147/JIR.S479444.

References

Marenholz I, Nickel R, Ruschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T . Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol. 2006; 118(4):866-71. DOI: 10.1016/j.jaci.2006.07.026. View

Howell M, Boguniewicz M, Pastore S, Novak N, Bieber T, Girolomoni G . Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol. 2006; 121(3):332-8. DOI: 10.1016/j.clim.2006.08.008. View

Gustafsson D, Sjoberg O, Foucard T . Development of allergies and asthma in infants and young children with atopic dermatitis--a prospective follow-up to 7 years of age. Allergy. 2001; 55(3):240-5. DOI: 10.1034/j.1398-9995.2000.00391.x. View

Warner J . A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol. 2001; 108(6):929-37. DOI: 10.1067/mai.2001.120015. View

Ong P, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T . Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002; 347(15):1151-60. DOI: 10.1056/NEJMoa021481. View

Leung D, Bieber T . Atopic dermatitis. Lancet. 2003; 361(9352):151-60. DOI: 10.1016/S0140-6736(03)12193-9. View

Nomura I, Goleva E, Howell M, Hamid Q, Ong P, Hall C . Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003; 171(6):3262-9. DOI: 10.4049/jimmunol.171.6.3262. View

Laouini D, Kawamoto S, Yalcindag A, Bryce P, Mizoguchi E, Oettgen H . Epicutaneous sensitization with superantigen induces allergic skin inflammation. J Allergy Clin Immunol. 2003; 112(5):981-7. DOI: 10.1016/j.jaci.2003.07.007. View

Leung D, Boguniewicz M, Howell M, Nomura I, Hamid Q . New insights into atopic dermatitis. J Clin Invest. 2004; 113(5):651-7. PMC: 351324. DOI: 10.1172/JCI21060. View

10.

Bowcock A, Cookson W . The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet. 2004; 13 Spec No 1:R43-55. DOI: 10.1093/hmg/ddh094. View

11.

Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B . The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004; 113(5):925-31. DOI: 10.1016/j.jaci.2004.01.778. View

12.

Hamid Q, Boguniewicz M, Leung D . Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 1994; 94(2):870-6. PMC: 296169. DOI: 10.1172/JCI117408. View

13.

Aalto-Korte K . Improvement of skin barrier function during treatment of atopic dermatitis. J Am Acad Dermatol. 1995; 33(6):969-72. DOI: 10.1016/0190-9622(95)90288-0. View

14.

Spergel J, Mizoguchi E, Brewer J, Martin T, Bhan A, Geha R . Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest. 1998; 101(8):1614-22. PMC: 508742. DOI: 10.1172/JCI1647. View

15.

Candi E, Schmidt R, Melino G . The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005; 6(4):328-40. DOI: 10.1038/nrm1619. View

16.

Howell M, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M . Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol. 2005; 125(4):738-45. DOI: 10.1111/j.0022-202X.2005.23776.x. View

17.

Boguniewicz M, Leung D . 10. Atopic dermatitis. J Allergy Clin Immunol. 2006; 117(2 Suppl Mini-Primer):S475-80. DOI: 10.1016/j.jaci.2005.10.018. View

18.

Howell M, Gallo R, Boguniewicz M, Jones J, Wong C, Streib J . Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity. 2006; 24(3):341-8. DOI: 10.1016/j.immuni.2006.02.006. View

19.

Palmer C, Irvine A, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee S . Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38(4):441-6. DOI: 10.1038/ng1767. View

20.

Homey B, Steinhoff M, Ruzicka T, Leung D . Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol. 2006; 118(1):178-89. DOI: 10.1016/j.jaci.2006.03.047. View